San Diego-based mostly Viking Therapeutics marked alone as a serious competitor from the weight loss drug industry in February soon after revealing promising data from the mid-stage trial of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when supplied to be a weekly injection As well as in March the co